In summary, we developed a strategy to modify NK cells with Gpc3 aptamers (G-NK cells), which can specifically target GPC3+ HCC tumor cells to significantly enhance NK cell cytotoxicity without genetic modification in vitro and in vivo. The gene discussed is GPC3; the disease is neoplasm.